Corcept, IBD Stock Of The Day, Setting Up Amid Booming Earnings Growth
Corcept Therapeutics, Stock Of The Day fell amid a medical sell-off, but has pared losses to near buy points. Earnings growth is booming. Continue Reading
YENOM NOTICIAS
Qué está moviendo el mercado.
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
3 Reasons to Sell CORT and 1 Stock to Buy Instead
3 Reasons to Sell CORT and 1 Stock to Buy Instead The past six months have been a windfall for Corcept's shareholders. The company's stock price has jumped 201%, hitting $122.93 per share. This was partly due to its solid quarterly results…
The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health Companies
For Immediate Release Chicago, IL – October 5 2026 – Zacks.com announces the list of stocks and ETFs featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the fin…
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
Wall Street has remained volatile over the past few months. Major indexes have hit record highs multiple times but have given up substantial gains as investors' sentiment remains low amid ongoing tensions in the Middle East and high inflat…
Unpacking Q2 Earnings: Merck (NYSE:MRK) In The Context Of Other Branded Pharmaceuticals Stocks
Unpacking Q2 Earnings: Merck (NYSE:MRK) In The Context Of Other Branded Pharmaceuticals Stocks Looking back on branded pharmaceuticals stocks' Q2 earnings, we examine this quarter's best and worst performers, including Merck (NYSE:MRK) and…
Is Aspen Pharmacare (APNHY) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Aspen Pharmacare (APNHY) one of those stocks right now? Let's take a closer look at the stock's year-…
Strong Commercial Execution and Pipeline Opportunities Propel Corcept Therapeutics (CORT)
BUFFALO Funds, an actively managed mutual fund advised by Kornitzer Capital Management, released its second-quarter 2026 investor letter for "Buffalo Mid Cap Discovery Fund". The letter can be downloaded here. The Fund returned 11.34% in t…
Corcept Announces Planned Leadership Transition
Sean Maduck to Retire; Justin Gunn Appointed President, Endocrinology REDWOOD CITY, Calif., September 23, 2026--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and deve…
Corcept Therapeutics (CORT) CHMP Backing Keeps Undervalued Narrative In Focus
Corcept Therapeutics (CORT) drew fresh attention after the European Medicines Agency's CHMP backed approval of relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer, following positive Phase 2 and Phase 3 ROSELLA data. Cor…
3 of Wall Street’s Favorite Stocks We Keep Off Our Radar
3 of Wall Street's Favorite Stocks We Keep Off Our Radar The stocks in this article have caught Wall Street's attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of…
Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle
On September 18, Corcept Therapeutics (NASDAQ:CORT) said Europe's drug regulator recommended approval for the cancer therapy that has already earned a spot in US cancer treatment guidelines. The Committee for Medicinal Products for Human U…
CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer
Corcept Therapeutics CORT announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Lifyorli (relacorilant) in combination with nab-pac…
Catalyst Watch: Trump-Xi in DC, Meta Connect, and McDonald's Investor Day
[Fearless girl statue standing against New York Stock Exchange Building] xavierarnau Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impac…
Branded Pharmaceuticals Stocks Q2 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
Branded Pharmaceuticals Stocks Q2 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN) Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let's have a look at Supernus Pharmac…
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)
REDWOOD CITY, Calif., September 18, 2026--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, meta…
Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026?
Corcept Therapeutics' CORT lead marketed drug, Korlym (mifepristone), which is approved for the treatment of Cushing's syndrome, has been witnessing strong demand. The majority of the company's top line is currently being driven by Korlym…
Corcept Grows to Mid-Cap on Institutional Support
CORT discovers, develops, and sells medications to treat severe metabolic, oncologic, and psychiatric disorders, focusing on the hormone cortisol (over 1,000 proprietary modulators) along with Cushing's syndrome. Its second-quarter fiscal…
2 Healthcare Stocks to Research Further and 1 We Find Risky
2 Healthcare Stocks to Research Further and 1 We Find Risky Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as…
Should iShares Core S&P Small-Cap ETF (IJR) Be on Your Investing Radar?
Launched on May 22, 2000, the iShares Core S&P Small-Cap ETF (IJR) is a passively managed exchange traded fund designed to provide a broad exposure to the Small Cap Blend segment of the US equity market. The fund is sponsored by Blackrock.…
Which Is the Better Healthcare ETF: Fidelity's Low-Cost FHLC or First Trust's High-Conviction FBT?
Fidelity MSCI Health Care Index ETF (NYSEMKT:FHLC) offers broad healthcare exposure at a fraction of the cost, while First Trust NYSE Arca Biotechnology Index Fund (NYSEMKT:FBT) provides an aggressive, concentrated focus on biotechnology i…
The Trade Desk to leave S&P 500 as Bloom Energy, Everpure, Illumina join index
[investor adjusting financial portfolio using digital market data, concept of asset rebalancing, investment strategy, risk management and wealth preservation] primeimages/iStock via Getty Images S&P Dow Jones Indices on Friday said it will…
Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600
NEW YORK, Sept. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 21, 2026, to co…
Bloom Energy surges on inclusion to S&P 500; Illumina, Everpure also added
[Stock market data with uptrend vector] sitox Bloom Energy (BE [https://seekingalpha.com/symbol/BE]) jumped 6.2% post-market Friday after the manufacturer of solid oxide fuel cell systems for on-site power generation was added [https://www…
United Therapeutics (UTHR) Down 8% Since Last Earnings Report: Can It Rebound?
It has been about a month since the last earnings report for United Therapeutics (UTHR). Shares have lost about 8% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue…
1 Growth Stock Set to Flourishand 2 We Brush Off
1 Growth Stock Set to Flourishand 2 We Brush Off Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market…
SPSM vs IJR: Which Small-Cap ETF Offers Better Value?
iShares Core S&P Small-Cap ETF (NYSEMKT:IJR) and State Street SPDR Portfolio S&P 600 Small Cap ETF (NYSEMKT:SPSM) offer nearly identical exposure to U.S. small-cap stocks, differing primarily in expense ratio, liquidity, and assets under m…
Branded Pharmaceuticals Stocks Q2 Teardown: Bristol-Myers Squibb (NYSE:BMY) Vs The Rest
Branded Pharmaceuticals Stocks Q2 Teardown: Bristol-Myers Squibb (NYSE:BMY) Vs The Rest The end of the earnings season is always a good time to take a step back and see who shined (and who didn't). Let's take a look at how branded pharmace…
Should iShares S&P Small-Cap 600 Growth ETF (IJT) Be on Your Investing Radar?
Launched on July 24, 2000, the iShares S&P Small-Cap 600 Growth ETF (IJT) is a passively managed exchange traded fund designed to provide a broad exposure to the Small Cap Growth segment of the US equity market. The fund is sponsored by Bl…
Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report?
A month has gone by since the last earnings report for Corcept Therapeutics (CORT). Shares have lost about 1.2% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue le…
White House is said to announce drug pricing deals with biotechs
The Trump administration is expected to announce a series of drug pricing deals with several mid-size biotech companies as early as Monday, adding to similar agreements reached with Big Pharma since late last year, Bloomberg News reported…
Q2 Rundown: Pfizer (NYSE:PFE) Vs Other Branded Pharmaceuticals Stocks
Q2 Rundown: Pfizer (NYSE:PFE) Vs Other Branded Pharmaceuticals Stocks Let's dig into the relative performance of Pfizer (NYSE:PFE) and its peers as we unravel the now-completed Q2 branded pharmaceuticals earnings season. Looking ahead, the…
1 Mid-Cap Stock for Long-Term Investors and 2 That Underwhelm
1 Mid-Cap Stock for Long-Term Investors and 2 That Underwhelm Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in f…
Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Corcept (NASDAQ:CORT)
Reflecting On Branded Pharmaceuticals Stocks' Q2 Earnings: Corcept (NASDAQ:CORT) Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let's have a look at Corcept (NASDAQ:CORT) and its…
XBI vs. FBT: Broad Biotech Exposure or Concentrated Bets?
The State Street SPDR S&P Biotech ETF (NYSEMKT:XBI) provides broad exposure to the biotech industry, while the First Trust NYSE Arca Biotechnology Index Fund (NYSEMKT:FBT) offers a much more concentrated, equal-weighted alternative. Biotec…
Mega Cap Growth vs Small Cap Growth: Which ETF Wins?
The Vanguard Morningstar Mega Cap Growth ETF (NYSEMKT:MGK) offers low-cost exposure to the largest U.S. growth stocks, while the State Street SPDR S&P 600 Small Cap Growth ETF (NYSEMKT:SLYG) targets smaller companies with high expansion po…
1 Surging Stock to Own for Decades and 2 We Brush Off
1 Surging Stock to Own for Decades and 2 We Brush Off Great things are happening to the stocks in this article. They're all outperforming the market over the last month because of positive catalysts such as a new product line, constructive…